GlobeNewswire: OptiNose, Inc. Contains the last 10 of 146 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T09:44:39ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/15/2847277/0/en/XHANCE-Approved-by-FDA-as-First-and-Only-Medication-Indicated-for-Treatment-of-Adults-with-Chronic-Rhinosinusitis-without-Nasal-Polyps.html?f=22&fvtc=4&fvtv=39549XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps2024-03-15T19:34:50Z<![CDATA[ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps]]>https://www.globenewswire.com/news-release/2024/03/07/2842112/0/en/Optinose-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Operational-Highlights.html?f=22&fvtc=4&fvtv=39549Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights2024-03-07T12:00:43Z<![CDATA[PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch of XHANCE for treatment of patients diagnosed with chronic sinusitis]]>https://www.globenewswire.com/news-release/2024/02/29/2838451/0/en/Optinose-Announces-Reporting-Date-for-Fourth-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=39549Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results2024-02-29T21:40:00Z<![CDATA[Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time]]>https://www.globenewswire.com/news-release/2024/01/18/2811788/0/en/Optinose-Announces-the-Publication-of-ReOpen-Phase-3-Clinical-Trial-Program-Evaluating-XHANCE-in-the-Journal-of-Allergy-and-Clinical-Immunology-In-Practice.html?f=22&fvtc=4&fvtv=39549Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice2024-01-18T17:00:00Z<![CDATA[XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis (chronic rhinosinusitis) in two randomized controlled Phase 3 Clinical Trials (ReOpen1 and ReOpen2)]]>https://www.globenewswire.com/news-release/2023/12/06/2791632/0/en/Optinose-Announces-3-Month-Extension-of-FDA-Review-Period-for-the-Supplemental-New-Drug-Application-for-XHANCE.html?f=22&fvtc=4&fvtv=39549Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE2023-12-06T12:00:00Z<![CDATA[The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis]]>https://www.globenewswire.com/news-release/2023/11/22/2784826/0/en/Optinose-to-Present-at-the-35th-Annual-Piper-Sandler-Healthcare-Conference.html?f=22&fvtc=4&fvtv=39549Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference2023-11-22T14:00:00Z<![CDATA[YARDLEY, Pa., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 35th Annual Piper Sandler Healthcare Conference on November 29, 2023, at 3:30 p.m. ET.]]>https://www.globenewswire.com/news-release/2023/11/09/2777182/0/en/Optinose-Reports-Third-Quarter-2023-Financial-Results-and-Operational-Updates.html?f=22&fvtc=4&fvtv=39549Optinose Reports Third Quarter 2023 Financial Results and Operational Updates2023-11-09T12:00:00Z<![CDATA[Company reports third quarter 2023 XHANCE net revenue of $19.8 million and increases full year 2023 XHANCE net revenue guidance]]>https://www.globenewswire.com/news-release/2023/10/27/2768376/0/en/Optinose-Announces-Reporting-Date-for-Third-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=39549Optinose Announces Reporting Date for Third Quarter 2023 Financial Results2023-10-27T12:00:00Z<![CDATA[Conference Call and Webcast to be held November 9, 2023, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held November 9, 2023, at 8:00 a.m. Eastern Time]]>https://www.globenewswire.com/news-release/2023/09/22/2747999/0/en/Optinose-to-Present-at-the-2023-Cantor-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=39549Optinose to Present at the 2023 Cantor Global Healthcare Conference2023-09-22T13:01:00Z<![CDATA[YARDLEY, Pa., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 2023 Cantor Global Healthcare Conference on September 27, 2023 at 4:45 p.m. ET.]]>https://www.globenewswire.com/news-release/2023/08/10/2722489/0/en/Optinose-Reports-Second-Quarter-2023-Financial-Results-and-Operational-Updates.html?f=22&fvtc=4&fvtv=39549Optinose Reports Second Quarter 2023 Financial Results and Operational Updates2023-08-10T11:00:00Z<![CDATA[Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year 2023 XHANCE net revenue guidance]]>